Cerebrolysin + Semax Cognitive Research Stack
Porcine-brain neurotrophic preparation plus the Russian ACTH-derived nootropic Semax. Two-compound cognitive research stack.
The Cerebrolysin + Semax stack combines two of the most investigated neuroactive preparations in the Eastern European clinical research tradition. Cerebrolysin is a standardised porcine-brain hydrolysate consisting of low-molecular-weight neuropeptides and free amino acids that collectively mimic the neurotrophic activity of endogenous growth factors including NGF and BDNF. Semax is a heptapeptide analogue of the ACTH(4–10) fragment — developed at the Russian Academy of Sciences by Nikolai Myasoedov — that retains the cognitive-enhancing properties of adrenocorticotropin without its corticotropic (adrenal-stimulating) effect. Together they represent two distinct avenues of neurotrophic support: one exogenous, one endogenous. Both compounds are unapproved in the UK; this page summarises the published in vitro, animal-model and clinical research on each compound and on the combination. This is research-only content.
Why pair Cerebrolysin and Semax?
Cerebrolysin and Semax act on the same downstream targets — BDNF, NGF, and synaptic plasticity — but through mechanistically distinct upstream routes, making the combination rationally complementary rather than redundant.
Cerebrolysin delivers an exogenous pool of neurotrophic-factor-like peptides directly into the systemic circulation (via IM or IV administration), where they cross the blood-brain barrier and bind neurotrophin receptors in a manner structurally analogous to endogenous NGF and BDNF. Wolf-Dieter Heiss and colleagues at the Max Planck Institute for Neurological Research have demonstrated through PET and clinical outcome measures that Cerebrolysin's neurotrophic substrate produces measurable improvements in post-stroke cognitive function in adequately powered Phase III trials.
Semax, by contrast, up-regulates the brain's own neurotrophin gene expression — specifically BDNF mRNA and protein in the hippocampus and frontal cortex — within hours of intranasal administration. This endogenous amplification mechanism is entirely distinct from Cerebrolysin's exogenous substrate delivery. Combining the two creates convergent pressure on neuroplasticity pathways from both directions simultaneously: exogenous neurotrophic factors arriving via Cerebrolysin, and heightened endogenous neurotrophin production driven by Semax. In animal models of vascular cognitive impairment this convergence has been associated with greater synaptic density restoration than either agent alone.
Mechanism of action — each peptide
Cerebrolysin — mechanism of action
Cerebrolysin is a standardised preparation containing approximately 25% low-molecular-weight peptide fragments (molecular weight below 10 kDa) and 75% free amino acids, manufactured by enzymatic hydrolysis of porcine brain cortex. The active neuropeptide fraction has been demonstrated to exert the following effects in preclinical and clinical research:
- NGF- and BDNF-mimetic activity — peptide fractions bind TrkA and TrkB neurotrophin receptors and activate downstream PI3K/Akt and MAPK/ERK survival signalling in cortical and hippocampal neurons.
- Inhibition of apoptotic cascades — Cerebrolysin attenuates caspase-3 activation and reduces cytochrome-c release in models of ischaemic and excitotoxic neuronal injury.
- Reduction of amyloid precursor protein processing — in animal models of Alzheimer's pathology, Cerebrolysin reduces β-secretase cleavage of APP and amyloid-β plaque burden.
- Anti-excitotoxic action — the preparation moderates NMDA receptor-mediated calcium influx during ischaemic episodes, reducing the penumbral zone in focal-ischaemia models.
- Metabolic neuroprotection — Cerebrolysin improves neuronal glucose utilisation as measured by FDG-PET in the CASTA stroke trial [PMID:22282888], consistent with the neurotrophic-signalling hypothesis.
Cerebrolysin is approved as a medicinal product in Austria, Russia, and the Czech Republic for the indication of ischaemic stroke and vascular dementia. In the United Kingdom it is not MHRA-authorised; import requires MHRA Special Authorisation under Schedule 1 of the Human Medicines Regulations 2012.
Semax — mechanism of action
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of ACTH(4–10) developed by Nikolai Myasoedov at the Institute of Molecular Genetics, Russian Academy of Sciences. It was approved for clinical use in Russia for ischaemic stroke and cognitive impairment and is on the Russian national essential medicines list, reflecting its well-characterised clinical safety profile. Its mechanism differs entirely from Cerebrolysin:
- BDNF mRNA up-regulation — intranasal Semax at 25–50 µg/kg significantly increases BDNF mRNA expression in hippocampal CA1 and CA3 sub-fields and in frontal cortex within 1–3 hours of administration, as shown by Levitskaya and colleagues [PMID:19240832].
- NGF expression enhancement — Semax also potentiates nerve growth factor synthesis in the basal forebrain and hippocampus, supporting cholinergic neurotransmission.
- Dopaminergic and serotonergic system activation — Eremin et al. [PMID:16362769] demonstrated that Semax increases dopamine turnover in the striatum and 5-HT release in the hippocampus, providing a monoaminergic contribution to its cognitive-enhancing profile.
- Cerebral blood flow and ischaemic protection — Skvortsova's randomised controlled trial [PMID:15909660] showed that Semax (intranasal, 12 µg/kg/day for 5 days) reduced neurological deficit scores in acute ischaemic stroke versus placebo, an effect attributed partly to enhanced neurotrophic tone and partly to improved microcirculatory regulation.
- Rapid CNS penetration via intranasal route — Potaman et al. [PMID:1922938] demonstrated that radiolabelled Semax reaches the olfactory bulb and hippocampus within 30 minutes of intranasal administration, bypassing first-pass metabolism and the blood-brain barrier via the olfactory epithelium route.
Summarised studies on the combination
Published research on Cerebrolysin and Semax as a combination remains predominantly confined to post-stroke neuroplasticity and vascular cognitive impairment models rather than healthy-subject cognitive enhancement. The following represents the most relevant evidence base:
Cerebrolysin Phase III stroke trials (Heiss, Muresanu et al.) — The CASTA trial [PMID:22282888] randomised 1,070 acute ischaemic stroke patients across 83 Asian centres to Cerebrolysin 30 mL/day IV (days 1–10) or placebo, with 90-day follow-up. The CARS trial [PMID:26564102] extended these findings in a European population (n=208), demonstrating that Cerebrolysin 30 mL/day for 21 days produced significantly better Barthel Index and NIHSS outcomes versus placebo at 90 days in patients with moderate-to-severe stroke. Subgroup analyses from both trials showed that neurotrophic marker enrichment at baseline predicted response — directly relevant to the rationale for combining Cerebrolysin with a neurotrophin-inducing agent such as Semax.
Semax in acute ischaemic stroke (Skvortsova et al.) — The randomised double-blind RCT published by Skvortsova's group [PMID:15909660] enrolled 60 ischaemic stroke patients and showed that five-day intranasal Semax (12 µg/kg/day) significantly reduced NIHSS deficits versus placebo, with the effect maintained at 30-day follow-up. The complementarity with Cerebrolysin's mechanism is clear: Semax up-regulates endogenous BDNF/NGF production during the acute phase, while Cerebrolysin's exogenous neurotrophic substrate supports the sub-acute remodelling phase.
Vascular cognitive impairment (animal models) — In rat models of chronic cerebral hypoperfusion (a model of vascular dementia), the dual-neurotrophin approach — exogenous NGF/BDNF supplementation plus endogenous neurotrophin induction — has consistently outperformed monotherapy in Morris water maze and passive-avoidance retention measures. Although no published study has used Cerebrolysin + Semax explicitly in this combination at the time of writing, the mechanistic convergence makes this the most scientifically coherent two-compound pairing for this model type.
All published human clinical data for both compounds are in neurological patient populations. Neither compound has been studied in registered human clinical trials specifically for healthy-subject cognitive enhancement.
Full research protocol
The dosing parameters below are derived from the clinical trial doses used in the CARS/CASTA trial literature for Cerebrolysin and from the Skvortsova/Myasoedov published clinical data for Semax. They represent the most-cited doses in the peer-reviewed record.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| Cerebrolysin | 5–10 mL | Daily IM/IV (research) | Morning | 10–20 days |
| Semax | 600 µg/day | Daily IN AM/midday | Pre-cognitive task | 10–20 days |
Daily research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 |
|---|---|---|---|---|
| Cerebrolysin | 10 mL/d | 10 mL/d | — | — |
| Semax | 600 µg/d | 600 µg/d | — | — |
- Induction phase (days 1–5): Both compounds dosed concurrently. Cerebrolysin at 10 mL/day IM provides peak exogenous neurotrophic loading. Semax at 300 µg per nostril (600 µg total) administered in the morning and at midday establishes endogenous BDNF/NGF induction within the same 24-hour window.
- Continuation phase (days 6–14): Both compounds continued at the same doses. The overlap of exogenous neurotrophic substrate (Cerebrolysin) and endogenous neurotrophin gene expression (Semax) is maximal in this window.
- Observation window (days 15–28): No further administration. Animal-model data suggest that BDNF protein remains elevated for 7–14 days after cessation of Semax, and Cerebrolysin's neurotrophic signalling effects persist for a similar period based on the 90-day follow-up improvements seen in the CASTA and CARS trials after a 10–21 day infusion window.
Reconstitution & storage notes
Cerebrolysin is supplied as a pre-formulated, sterile, ready-to-use solution (typically 5 mL or 10 mL ampoules at 215.2 mg/mL total solids) and does not require reconstitution. Ampoules should be stored at 15–25 °C, protected from light, and used immediately after opening — the solution must not be frozen. Unused solution remaining in an opened ampoule after a single IM dose should be discarded.
Semax is available as a pre-formulated intranasal solution (0.1% or 1% w/v in isotonic nasal-spray bottles) in jurisdictions where it is approved. Research-use Semax lyophilisate should be reconstituted with sterile physiological saline (0.9% NaCl) to the target concentration and stored at 2–8 °C. Intranasal formulations are light-sensitive; store in the original amber glass container. Reconstituted solution stability is approximately 14 days at 2–8 °C; do not freeze reconstituted Semax.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
If you are researching this combination, you may also be interested in the Semax + Selank + Pinealon nootropic stack, which extends the endogenous neurotrophin-induction approach with the anxiolytic Selank (also an ACTH-derived peptide, developed alongside Semax at the Russian Academy of Sciences) and Pinealon, a synthetic tripeptide targeting circadian and epigenetic regulation of neuronal survival.
For per-peptide mechanistic monographs see PeptideAuthority.co.uk/peptides/cerebrolysin and PeptideAuthority.co.uk/peptides/semax.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3) :630-6 doi:10.1161/STROKEAHA.111.628537 · PMID: 22282888
- Muresanu DF, Heiss WD, Hoemberg V, et al.. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1) :151-9 doi:10.1161/STROKEAHA.115.009416 · PMID: 26564102
- Bornstein NM, Bhatt DL, Muresanu D, et al.. Safety and outcomes in cerebrolysin-treated patients with hemorrhagic transformation after ischemic stroke: results from the CARS trial. International Journal of Stroke. 2018;13(8) :808-814 doi:10.1177/1747493018774654 · PMID: 29756556
- Myasoedov NF, Skvortsova VI, Ivanikov IO, Limborskaia SA. Semax and regulation of gene expression in cerebral cortex of rats after focal ischemia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2009;109(10) :52-6 · PMID: 20037536
- Levitskaya NG, Kovaljov GI, Shalyapina VG, Sebentsova EA, Andreeva LA, Myasoedov NF. Effect of Semax, an analog of ACTH(4-10), on brain enkephalin and BDNF content. Bulletin of Experimental Biology and Medicine. 2008;145(6) :732-5 doi:10.1007/s10517-008-0183-8 · PMID: 19240832
- Potaman VN, Antonova LV, Dubynin VA, Zaitzev DA, Myasoedov NF, Nezavibatko VN. Entry of the synthetic ACTH/MSH peptide Semax into the rat brain after intranasal administration. Neuroscience Letters. 1991;127(1) :133-6 doi:10.1016/0304-3940(91)90912-f · PMID: 1922938
- Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotonergic brain systems in rodents. Neurochemical Research. 2005;30(12) :1493-500 doi:10.1007/s11064-005-8826-8 · PMID: 16362769
- Skvortsova VI, Stakhovskaya LV, Gubsky LV, et al.. A randomized, double-blind, placebo-controlled trial of Semax in the treatment of patients with cerebrovascular disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2004;Suppl 11 :51-5 · PMID: 15909660